CymaBay Therapeutics (CBAY) Stock Price, News & Analysis

0.00 (0.00%)
(As of 04/1/2024)
Today's Range
50-Day Range
52-Week Range
73 shs
Average Volume
4.11 million shs
Market Capitalization
$3.73 billion
P/E Ratio
Dividend Yield
Price Target

CymaBay Therapeutics MarketRank™ Stock Analysis

Analyst Rating
2.08 Rating Score
11.8% Downside
$28.65 Price Target
Short Interest
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Selling Shares
$191,820 Sold Last Quarter
Proj. Earnings Growth
From ($1.38) to ($1.37) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.94 out of 5 stars

Medical Sector

792nd out of 909 stocks

Pharmaceutical Preparations Industry

371st out of 423 stocks

CBAY stock logo

About CymaBay Therapeutics Stock (NASDAQ:CBAY)

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

CBAY Stock Price History

CBAY Stock News Headlines

The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Gilead Sciences Completes Acquisition Of CymaBay Therapeutics
CBAY Jul 2024 34.000 call
CBAY Apr 2024 31.000 put
CBAY Oct 2024 33.000 call
Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
CBAY Oct 2024 29.000 put
Maintaining Hold on CymaBay Amid Gilead Acquisition Deal Closure
CymaBay Therapeutics 4Q Loss/Shr 35c >CBAY
CBAY Jan 2026 37.000 call
CBAY Feb 2024 33.000 call
CBAY Jan 2025 8.000 put
See More Headlines
Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
12 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$31.07 million
Book Value
$2.58 per share


Free Float
Market Cap
$3.73 billion
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

CBAY Stock Analysis - Frequently Asked Questions

Should I buy or sell CymaBay Therapeutics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 11 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CBAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CBAY, but not buy additional shares or sell existing shares.
View CBAY analyst ratings
or view top-rated stocks.

What is CymaBay Therapeutics' stock price target for 2024?

12 Wall Street research analysts have issued 1 year price targets for CymaBay Therapeutics' stock. Their CBAY share price targets range from $15.00 to $32.50. On average, they predict the company's stock price to reach $28.65 in the next twelve months. This suggests that the stock has a possible downside of 11.8%.
View analysts price targets for CBAY
or view top-rated stocks among Wall Street analysts.

How have CBAY shares performed in 2024?

CymaBay Therapeutics' stock was trading at $23.62 on January 1st, 2024. Since then, CBAY stock has increased by 37.5% and is now trading at $32.48.
View the best growth stocks for 2024 here

When is CymaBay Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our CBAY earnings forecast

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) announced its quarterly earnings data on Wednesday, February, 28th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.04. The biopharmaceutical company earned $0.06 million during the quarter, compared to analysts' expectations of $0.42 million.

What ETFs hold CymaBay Therapeutics' stock?

ETFs with the largest weight of CymaBay Therapeutics (NASDAQ:CBAY) stock in their portfolio include AltShares Merger Arbitrage ETF (ARB) and AltShares Event-Driven ET (EVNT).AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC).

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CBAY) was last updated on 4/24/2024 by Staff

From Our Partners